Research in Context is a structured summary that editors at The Lancet’s journals ask all authors to provide when submitting an original research article. Read more
Stay at the forefront of gastric and gastroesophageal junction cancer care with insights from the Lancet, featuring groundbreaking research and authoritative reviews that inform the latest advances in diagnosis, treatment, and patient care.
In an expert-setting RCT reported as the first of its kind, endoscopic gastroenterostomy became functional more quickly than surgical gastroenterostomy; cost-effectiveness and non-expert use remain to be evaluated.
The Lancet Group reaches millions of clinicians and researchers worldwide.
In PD-L1 CPS ≥5 disease, the phase 3 study reported improved event-free survival and pathological complete response with neoadjuvant serplulimab plus chemotherapy followed by adjuvant serplulimab monotherapy versus neoadjuvant and adjuvant chemotherapy.
Limited to patients with cT4a N+ M0 or cT4b Nany M0 disease undergoing D2 gastrectomy, the trial reported an overall survival advantage with perioperative or adjuvant SOX versus adjuvant CapOx.
An open-label phase 1 study reported objective response and disease-control rates for the investigational CLDN18.2-specific antibody–drug conjugate CMG901, with higher rates in patients with greater CLDN18.2 expression; further trials are ongoing.
In this phase 3 trial, safety was reported as consistent with known profiles overall, but discontinuations and endocrine-related adverse events were more frequent with nivolumab plus chemotherapy than with placebo plus chemotherapy after resection.
In previously untreated, locally advanced or metastatic disease, pembrolizumab plus chemotherapy significantly improved overall survival, progression-free survival, and objective response rate versus placebo plus chemotherapy; the authors described toxicity as manageable.
An open-label randomised phase 3 trial reports similar survival estimates after early termination, while noting limited FLOT enrolment cannot be interpreted independently.
An early, first-in-setting study suggests adding investigational regorafenib to nivolumab and chemotherapy may be safe and active; a randomised phase 3 trial is planned to confirm these preliminary findings.
In patients with CLDN18.2-positive, HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma, adding investigational zolbetuximab to chemotherapy prolonged progression-free and overall survival versus chemotherapy alone, with more nausea and vomiting leading to discontinuation.
With no second-line therapy currently approved in China, the authors report findings consistent with the global RAINBOW study and suggest this combination might be a treatment option in this setting.
The ENDOANGEL-LD AI system reduced gastric neoplasm miss rates compared with standard upper gastrointestinal endoscopy; the authors describe potential future support for targeted biopsies.